More transparency needed
This article was originally published in Scrip
Executive Summary
While it was no surprise that the regulators have come down heavy on GSK's Avandia, the news that the US Food & Drug Administration and the European Medicines Agency should diverge in their response to well documented safety concerns was less predictable. Of course there would be more regulatory certainty if the European assessment processes were more transparent.